154 Participants Needed

CVL-865 for Seizures

Recruiting at 73 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Cerevel Therapeutics, LLC
Stay on Your Current MedsYou can continue your current medications while participating
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

This trial is testing a new medication called CVL-865 for people whose seizures are not controlled by current treatments. The medication works by balancing brain activity to help reduce seizures. CVL-865 is one of the newer antiepileptic drugs with a novel mode of action compared to more established treatments.

Research Team

EH

Eliza Hueda, MD

Principal Investigator

Cerevel Therapeutics, LLC

Eligibility Criteria

This trial is for adults with drug-resistant focal onset seizures, who've tried at least two anti-epileptic drugs without success and are currently on 1 to 3 stable AEDs. They must have had a minimum of eight seizures in the last eight weeks and been diagnosed with epilepsy for at least two years. Participants need a BMI between 17.5 to 40 kg/m^2 and weigh over 50 kg.

Inclusion Criteria

I agree to use a condom for 94 days after my last dose of the trial medication.
I have been diagnosed with focal epilepsy for at least 2 years.
I have tried at least 2 epilepsy drugs without success and am currently on 1 to 3 stable epilepsy drugs.
See 5 more

Exclusion Criteria

I am not currently using, nor likely to use, any medications not allowed by the study.
Your heart's electrical activity measured by ECG shows specific patterns that are too long.
I have trouble swallowing.
See 13 more

Treatment Details

Interventions

  • CVL-865
  • Placebo
Trial OverviewThe study tests CVL-865 as an additional treatment against placebo in people with focal onset seizures that don't respond well to other medications. The goal is to see if CVL-865 can reduce seizure frequency safely and tolerably.
Participant Groups
3Treatment groups
Experimental Treatment
Placebo Group
Group I: Low Dose: CVL-865 7.5 mgExperimental Treatment1 Intervention
Participants will receive CVL-865 tablets orally BID up to the maximum dose of 7.5 mg until Day 92 during the treatment period.
Group II: High Dose: CVL-865 25 mgExperimental Treatment1 Intervention
Participants will receive CVL-865 tablets orally twice daily (BID) up to the maximum dose of 25 milligrams (mg) until Day 92 during the treatment period.
Group III: PlaceboPlacebo Group1 Intervention
Participants will receive a placebo matched to CVL-865 tablets orally BID until Day 92 during the treatment period.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Cerevel Therapeutics, LLC

Lead Sponsor

Trials
37
Recruited
5,500+